With the clock ticking, scientists working with human embryonic stem cells were grappling Tuesday with how to use their remaining federal research funds before a court ruling forces them to bring their work to an abrupt end.
Recent Posts
- Infant becomes world’s first patient to undergo personalized gene-editing treatment
- Biotech Tango dances away from preclinical work to extend cash runway, while Avalo lays out spending options
- Embryonic macrophages found to control blood stem cell numbers in bone marrow
- Federal appeals court sends CRISPR-Cas9 patent case back to patent office for reconsideration
- The stem cell race for Parkinson’s disease: Recent studies show significant promise
- New Cell Therapy For Resistant Hodgkins Patients